List of Excipients in Branded Drug CEFAZOLIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	CEFAZOLIN	cefazolin sodium	0338-3508	ANHYDROUS DEXTROSE
Baxter Healthcare Corporation	CEFAZOLIN	cefazolin sodium	0338-3508	HYDROCHLORIC ACID
Baxter Healthcare Corporation	CEFAZOLIN	cefazolin sodium	0338-3508	SODIUM BICARBONATE

Generic Drugs Containing CEFAZOLIN

Company	Ingredient	NDC	Excipient
Baxter Healthcare Corporation	cefazolin sodium	0338-3503	DEXTROSE MONOHYDRATE
Baxter Healthcare Corporation	cefazolin sodium	0338-3503	HYDROCHLORIC ACID
Baxter Healthcare Corporation	cefazolin sodium	0338-3503	SODIUM BICARBONATE

What are the Most Frequently-Used Excipients in CEFAZOLIN?

# Of NDCs	Excipient
1	DEXTROSE MONOHYDRATE
1	HYDROCHLORIC ACID
1	SODIUM BICARBONATE

Cefazolin Excipient Strategy and Commercial Opportunities in Injectable Antibiotics

Last updated: August 14, 2026

Cefazolin is a mature, generic cephalosporin with limited active-ingredient patent protection and substantial price competition. The strongest commercial opportunities are in ready-to-use injectable presentations, improved stability, reduced preparation burden, pediatric dosing, closed-system packaging, and hospital supply reliability. Excipient selection must prioritize parenteral safety, cefazolin stability, container compatibility, particulate control, and rapid regulatory review.

What is the current pharmaceutical formulation of cefazolin?

Cefazolin is marketed primarily as cefazolin sodium for intravenous or intramuscular administration. The main dosage forms are sterile powder for reconstitution and ready-to-use or premixed injectable solutions.

Formulation attribute	Typical commercial approach
Active ingredient	Cefazolin sodium
Primary route	Intravenous injection or infusion; intramuscular injection
Main dosage strengths	500 mg, 1 g, and 2 g presentations are common
Powder dosage form	Sterile, nonpyrogenic cefazolin sodium requiring reconstitution
Solution dosage form	Cefazolin sodium in a compatible aqueous vehicle
Common vehicles	Water for Injection, 0.9% sodium chloride, or 5% dextrose, depending on product
Preservatives	Generally avoided in single-dose parenteral products
Primary users	Hospitals, ambulatory surgery centers, emergency departments, and outpatient infusion providers
Regulatory route for generics	Abbreviated New Drug Application under section 505(j) of the Federal Food, Drug, and Cosmetic Act

Approved labels identify cefazolin sodium as the active component and specify product-specific reconstitution, dilution, storage, and administration conditions. Excipients differ by presentation and manufacturer. A powder vial can have a very limited inactive formulation, while a premixed solution requires a vehicle, pH control, container system, and stability package. [1]

What excipients are most relevant to cefazolin products?

The commercial excipient strategy depends on whether the product is a powder vial, a conventional liquid, a premix, or a ready-to-administer system.

Powder-for-reconstitution products

A sterile cefazolin powder can minimize liquid-phase degradation during storage. The formulation may contain only cefazolin sodium, with no functional excipient beyond the drug substance. This design reduces excipient-related compatibility risk and simplifies inactive-ingredient review.

Its main disadvantages are operational:

• Pharmacy or nursing staff must reconstitute the dose.
• Diluent selection can create preparation errors.
• Vial handling increases manipulation and contamination risk.
• Preparation time is higher in high-volume surgical settings.
• The product generates more packaging and sharps waste.

A powder product remains commercially competitive when manufacturing cost, shelf life, and broad hospital contracting are the primary objectives.

Ready-to-use and premixed solutions

Liquid cefazolin products can eliminate reconstitution and support standardized administration. Their excipient system may include:

• Water for Injection.
• Sodium chloride solution.
• Dextrose solution.
• pH-adjusting agents, where justified.
• Nitrogen or other headspace controls, depending on packaging.
• Container-contact materials selected to limit adsorption and extractables.

A liquid formulation creates greater stability demands because cefazolin is exposed to water, temperature, oxygen, light, and container-contact surfaces throughout its shelf life. The development target should be a clinically meaningful storage period under standard hospital conditions, not only short-term stability after dilution.

Buffered systems

Buffering can improve pH control but may accelerate degradation or increase the ionic burden of an injectable product. A buffer should be used only when forced by stability, solubility, or compatibility data.

Potential systems include phosphate, citrate, or other pharmaceutically accepted buffers. Each creates additional assessment requirements for:

• Cefazolin chemical stability.
• Osmolality.
• Injection-site tolerability.
• Intravenous compatibility.
• Precipitation after admixture.
• Regulatory justification for the inactive ingredient.

For cefazolin, an unbuffered or minimally adjusted formulation may offer a cleaner regulatory and manufacturing profile if it meets stability requirements.

Tonicity agents

Sodium chloride and dextrose can make a cefazolin solution more suitable for intravenous administration. Tonicity adjustment must account for the final concentration, infusion volume, patient population, and route.

A concentrated, low-volume product may be useful for operating rooms and emergency departments. A larger-volume premix may reduce manipulation for inpatient infusion. These are separate commercial propositions and should not be treated as interchangeable.

How should an excipient strategy address cefazolin stability?

Cefazolin development should use a formulation screen that evaluates pH, concentration, temperature, oxygen exposure, light, and container-contact effects.

Development variable	Commercial relevance
pH	Controls degradation rate, solubility, and injection tolerability
Drug concentration	Determines vial size, infusion volume, and dose flexibility
Temperature	Drives refrigerated, controlled-room-temperature, or frozen distribution
Oxygen exposure	Can affect chemical stability and headspace requirements
Light exposure	Determines secondary packaging and handling instructions
Container material	Affects adsorption, leachables, extractables, and permeability
Diluent	Determines hospital compatibility and preparation instructions
Freeze-thaw exposure	Critical for premixed and frozen products
Reconstitution time	Directly affects pharmacy workflow
In-use stability	Supports multidose or extended-use claims where permitted

The most attractive target is a cefazolin solution stable long enough to support normal hospital inventory without refrigeration or special handling. A formulation that requires freezing or frequent temperature excursions may lose its operational advantage over powder vials.

Stability claims must be supported by validated analytical methods, including assay, degradation products, pH, particulate matter, sterility, bacterial endotoxins, and container-closure integrity. Cefazolin products also require compatibility work with infusion bags, tubing, syringes, and commonly co-administered solutions.

What formulations are protected by cefazolin patents?

Cefazolin is a mature small-molecule antibiotic. Its original compound and core use claims are no longer meaningful barriers to generic competition. Commercial differentiation is more likely to depend on formulation know-how, manufacturing controls, packaging, device integration, and supply reliability than on composition-of-matter patents.

Potentially protectable subject matter includes:

• Extended-stability cefazolin solutions.
• Specific pH and concentration ranges.
• Freeze-dried or spray-dried compositions.
• Dual-chamber delivery systems.
• Ready-to-use syringe or infusion-bag presentations.
• Container systems that reduce degradation or adsorption.
• Manufacturing processes that improve sterility assurance or yield.
• Combination packaging with proprietary administration components.
• Specific methods of reducing preparation errors in institutional use.

A formulation patent must provide a measurable technical effect. Broad claims covering cefazolin with routine pharmaceutical excipients face substantial validity and obviousness risk, particularly where the excipient is already used in approved parenteral products.

What is the FDA regulatory status of cefazolin?

Cefazolin is an FDA-approved antibacterial drug available through multiple generic injectable products. The regulatory center of gravity is the ANDA pathway, not a new-drug pathway, when the proposed product demonstrates sameness to a reference product in active ingredient, dosage form, strength, route, and labeling requirements.

A differentiated formulation may require a different regulatory assessment if it changes:

• Dosage form.
• Route of administration.
• Concentration or administration method.
• Labeling claims.
• In-use stability.
• Delivery system.
• Clinical performance or exposure.

The FDA’s Inactive Ingredient Database can help identify precedent for parenteral excipients, but prior use does not eliminate the need to establish suitability for the proposed product and route. [2] For a novel delivery platform, a 505(b)(2) application may be relevant, although the commercial case must justify the greater regulatory burden against a low-cost generic market.

What is the Orange Book status of cefazolin?

Cefazolin products are primarily generic injectable products listed through approved abbreviated applications. The Orange Book is relevant for reference-product identification, therapeutic-equivalence information, and any listed patents or exclusivity associated with a specific product. [3]

Cefazolin does not present the typical late-life branded product profile in which a single active patent blocks generic entry. A current Orange Book review should distinguish:

• Cefazolin sodium reference products.
• Approved ANDA products.
• Therapeutic-equivalence codes.
• Any product-specific patents.
• Any remaining exclusivity attached to a particular formulation or indication.

The practical market barrier is usually manufacturing, sterile-facility capacity, procurement qualification, and shortage risk rather than patent expiry.

When does cefazolin lose exclusivity?

Cefazolin’s original market exclusivity has expired. Generic competition is established, and the principal active-ingredient patent barrier is no longer commercially relevant.

For new cefazolin products, exclusivity may arise only from a new formulation, delivery system, or regulatory designation. Any such exclusivity would be product-specific and would not restore broad control over cefazolin sodium.

Potential regulatory periods include:

• Orphan-drug exclusivity, if an eligible rare-disease product were approved.
• Pediatric exclusivity, if applicable to a qualifying product.
• New chemical entity exclusivity, which does not apply to cefazolin as an established active ingredient.
• Three-year exclusivity for certain qualifying clinical investigations supporting a new drug application, subject to statutory requirements.

These mechanisms are unlikely to create a broad commercial moat for conventional cefazolin injection.

Are there Paragraph IV challenges for cefazolin?

Paragraph IV litigation is not a central cefazolin market issue. Because cefazolin has long been genericized and the original compound patents are expired, a new ANDA applicant would generally face fewer listed-patent barriers than applicants targeting recently launched branded products.

Risk can still arise from:

• A newly listed formulation patent.
• A proprietary premix or device patent.
• A patent covering a specific stability range.
• A patent covering a combination of cefazolin and a delivery system.
• Incorrect or incomplete patent certifications.
• Litigation over non-infringement, validity, or regulatory exclusivity.

For conventional cefazolin sodium powder, Paragraph IV exposure is generally lower than for proprietary ready-to-use presentations. The relevant diligence should focus on current FDA listings, patent-family status, and actual claims rather than the age of the cefazolin molecule.

Which companies are challenging or competing in cefazolin?

Competition is fragmented across generic injectable manufacturers, contract manufacturers, and hospital-supply companies. The competitive field can include companies such as:

• Baxter International.
• Fresenius Kabi.
• Hikma Pharmaceuticals.
• Sandoz.
• Pfizer, including legacy Hospira products.
• Eugia and other injectable-generic suppliers.
• Regional sterile injectable manufacturers.
• Hospital purchasing organizations and outsourced pharmacy providers.

The exact supplier mix varies by dose, presentation, country, hospital contract, and shortage conditions. In the United States, purchasing decisions often prioritize:

1. Reliable supply.
2. FDA compliance history.
3. Contract price.
4. Product availability by strength.
5. Administration convenience.
6. Recall and shortage performance.
7. Packaging and pharmacy workflow.

A supplier with a modest formulation improvement can gain share if it avoids recurring backorders or reduces preparation labor.

What commercial opportunities exist for cefazolin excipients?

Ready-to-use surgical prophylaxis

Cefazolin is widely used for perioperative prophylaxis. A ready-to-use syringe, vial, or small-volume bag can reduce reconstitution steps before surgery. The strongest target customers are hospitals with high orthopedic, cardiac, abdominal, and general surgical volumes.

The product must support rapid identification, low preparation burden, and reliable room-temperature handling. Unit-dose packaging and barcode compatibility can increase procurement value.

Extended-stability premixes

A premixed product with a practical shelf life can replace pharmacy-compounded doses. The value proposition is strongest where sterile compounding capacity is constrained or where hospitals face nursing shortages and preparation-error concerns.

A differentiated premix should quantify:

• Preparation time avoided.
• Reduction in pharmacy manipulations.
• Waste reduction.
• Compatibility with existing infusion systems.
• Storage requirements.
• Dose availability during peak surgical periods.

Dual-chamber systems

A dual-chamber bag separates cefazolin powder from the diluent until activation. This approach can improve storage stability while preserving bedside convenience. It is technically more complex and may require specialized container manufacturing, activation testing, and human-factors validation.

The platform may support premium pricing if it provides a measurable advantage over ordinary powder vials and premixed liquids.

Low-volume pediatric products

Pediatric hospitals may value flexible concentrations, small-volume syringes, and reduced calculation or dilution steps. The formulation must control dosing accuracy and avoid excipients that create avoidable pediatric exposure concerns.

Small-volume presentations can also support ambulatory surgery and outpatient infusion markets.

Supply-resilient sterile manufacturing

Cefazolin is a candidate for a manufacturing-led opportunity. A producer with validated sterile capacity, multiple drug-substance sources, and redundant fill-finish capability can compete on continuity of supply.

Excipient choices should support:

• Standardized raw materials.
• High-yield filling.
• Reduced aseptic interventions.
• Robust container-closure performance.
• Simplified global registration.
• Long shelf life with ordinary distribution.

How strong is the patent estate for cefazolin excipient products?

The patent estate is weak for conventional cefazolin powder but can be moderate for a genuinely differentiated delivery system.

Product concept	Patent strength	Regulatory complexity	Commercial potential
Conventional cefazolin powder vial	Low	Low to moderate	High volume, low margin
Cefazolin in saline premix	Low to moderate	Moderate	Moderate to high
Ready-to-use syringe	Moderate	Moderate	High in procedural settings
Dual-chamber bag	Moderate to strong	High	High if workflow benefits are proven
Novel stabilizer system	Moderate	Moderate to high	Dependent on stability advantage
Combination device and formulation	Stronger potential	High	Potential premium, narrower market
Pediatric low-volume product	Moderate	Moderate	Targeted institutional opportunity

Patent claims should focus on unexpected stability, improved compatibility, reduced degradation, or a specific device-formulation interaction. Merely substituting one conventional diluent for another is unlikely to produce durable protection.

What manufacturing and intellectual-property barriers affect cefazolin?

The principal barriers are operational rather than molecular. Sterile injectable manufacturing requires validated aseptic processes, environmental monitoring, container-closure integrity, particulate control, endotoxin control, and qualified suppliers.

Key technical risks include:

• Cefazolin degradation during terminal sterilization.
• Incompatibility with elastomers or plastic bags.
• Precipitation after dilution.
• Visible and subvisible particles.
• Leachables from flexible containers.
• Variable reconstitution time.
• Stability loss during transport.
• Inconsistent fill volumes.
• Microbial contamination during multidose handling.

A formulation that enables terminal sterilization could have a manufacturing advantage, but the process must not compromise cefazolin potency or impurity limits. Where terminal sterilization is unsuitable, aseptic processing increases cost and facility dependence.

How does cefazolin compare with competing prophylactic antibiotics?

Antibiotic	Main commercial role	Formulation opportunity	Competitive pressure
Cefazolin	Standard surgical prophylaxis and susceptible bacterial infections	RTU syringe, premix, dual-chamber bag	Very high generic competition
Cefuroxime	Surgical prophylaxis and respiratory infections	Premixed injectable products	High
Ceftriaxone	Broad-spectrum hospital and outpatient use	Ready-to-use and fixed-dose systems	High
Clindamycin	Alternative for beta-lactam allergy	Stable premix and unit-dose formats	High
Vancomycin	Resistant Gram-positive infections	Reconstituted and premixed infusion systems	High, with greater preparation complexity

Cefazolin has a stronger prophylaxis position than many alternatives, but its low price limits the ability to charge for minor formulation improvements. The commercial case must be tied to labor savings, reduced waste, lower medication-error risk, or supply continuity.

What generic launch risks exist for a new cefazolin product?

A new entrant faces several launch risks:

• Price erosion from multiple ANDA suppliers.
• Hospital contracts favoring incumbent vendors.
• Limited willingness to pay for a conventional formulation.
• FDA inspection or sterile-manufacturing delays.
• Shortage-driven demand that disappears after supply normalizes.
• Inadequate stability in commercial packaging.
• Device compatibility failures.
• Weak differentiation in pharmacy workflow.
• Low annual volume for specialized strengths.
• Procurement requirements for national distribution.

The most defensible launch strategy is usually a focused institutional product rather than another undifferentiated powder vial. A ready-to-use product should pursue hospital economics with documented preparation-time savings and supply commitments.

What geographic opportunities exist for cefazolin excipient products?

In the United States, hospital purchasing and FDA manufacturing requirements dominate. Europe emphasizes national tendering, hospital formularies, and country-specific reimbursement. Emerging markets may offer demand for powder vials but have greater sensitivity to price, cold-chain conditions, and local manufacturing requirements.

A global formulation should minimize excipient complexity and use internationally recognized parenteral ingredients. Products relying on a novel buffer or proprietary container may require broader regional stability and extractables packages.

The strongest geographic opportunities are markets with:

• High surgical volumes.
• Frequent injectable-antibiotic shortages.
• Limited pharmacy compounding capacity.
• Growth in ambulatory surgery.
• Strong demand for premixed products.
• Procurement systems that reward supply reliability.

What is the revenue exposure and investment case?

Conventional cefazolin revenue is volume-driven and margin-constrained. Revenue exposure is most sensitive to hospital contracts, generic price erosion, manufacturing uptime, and shortage events.

A differentiated cefazolin product can support better economics if it captures one of four value pools:

1. Reduced nursing or pharmacy preparation time.
2. Lower medication and compounding risk.
3. Lower wastage through unit-dose packaging.
4. Higher availability during injectable-drug shortages.

The investment case is strongest for a platform that can extend beyond cefazolin to ceftriaxone, cefuroxime, clindamycin, and other hospital injectables. A single-product strategy has limited upside unless it secures a strong institutional contract or solves a recognized supply problem.

Key Takeaways

• Cefazolin is a mature generic injectable with no meaningful original-molecule exclusivity remaining.
• Conventional powder vials offer limited patent differentiation and face intense price competition.
• The best excipient opportunities are in ready-to-use syringes, premixed bags, dual-chamber systems, and stable low-volume presentations.
• Excipient selection should prioritize stability, compatibility, osmolality, particulate control, and global regulatory acceptability.
• The commercial moat is more likely to come from packaging, delivery systems, sterile manufacturing, and supply reliability than from a simple excipient substitution.
• Paragraph IV risk is generally limited for conventional cefazolin but can increase for newly patented formulations or delivery systems.
• No biosimilar pathway applies because cefazolin is a small-molecule antibiotic.
• A successful product should quantify workflow savings and supply continuity rather than rely solely on a formulation claim.

FAQs About Cefazolin Excipient and Formulation Opportunities

Can cefazolin be formulated without preservatives?

Yes. Single-dose cefazolin injectable products commonly avoid preservatives. A preservative-free design is generally preferable for intravenous and intramuscular hospital use when the container system and in-use instructions support it.

Is sodium chloride the best diluent for cefazolin?

Sodium chloride is a common diluent, but it is not universally optimal. The choice depends on cefazolin stability, final osmolality, infusion volume, container compatibility, and the target patient population.

Can a cefazolin premix receive meaningful patent protection?

Yes, but the claims must cover a specific technical advantage, such as unexpected stability, container compatibility, or a device-formulation combination. A routine cefazolin solution in a conventional diluent is less likely to support durable patent protection.

Are cefazolin products subject to biosimilar competition?

No. Cefazolin is a chemically synthesized small molecule. Competition occurs through generic drug applications, not biosimilar applications.

What cefazolin product is most attractive for hospital commercialization?

A ready-to-use or dual-chamber product with strong stability, barcode-ready unit dosing, minimal preparation, and dependable supply offers the clearest commercial differentiation from standard powder vials.

References

1. U.S. Food and Drug Administration. (2024). Cefazolin sodium injection prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
4. United States Pharmacopeia. (2024). Cefazolin sodium monograph and general chapters for sterile injectable products. USP-NF.
5. U.S. Food and Drug Administration. (2024). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
6. World Health Organization. (2023). WHO model list of essential medicines. World Health Organization.